| Malignant neoplasm of breast
Lynparza vs Talzenna
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Lynparza vs Talzenna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTalzenna has a higher rate of injection site reactions vs Lynparza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Talzenna but not Lynparza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lynparza
Talzenna
At A Glance
Oral
Twice daily
PARP inhibitor
Oral
Daily
PARP inhibitor
Indications
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
- Malignant neoplasm of breast
- Adenocarcinoma of pancreas
- Hormone refractory prostate cancer
- Malignant neoplasm of breast
- Hormone refractory prostate cancer
Dosing
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line BRCAm maintenance) 300 mg orally twice daily; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line HRD-positive, + bevacizumab) 300 mg orally twice daily with bevacizumab 15 mg/kg every 3 weeks; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent BRCAm maintenance) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Malignant neoplasm of breast (adjuvant, gBRCAm HER2-negative high risk early) 300 mg orally twice daily for a total of 1 year, or until disease recurrence or unacceptable toxicity.
Malignant neoplasm of breast (metastatic, gBRCAm HER2-negative) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Adenocarcinoma of pancreas 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (HRR gene-mutated mCRPC, monotherapy) 300 mg orally twice daily with concurrent GnRH analog or prior bilateral orchiectomy; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (BRCAm mCRPC, + abiraterone) 300 mg orally twice daily with abiraterone 1000 mg once daily and prednisone or prednisolone 5 mg twice daily; continue until disease progression or unacceptable toxicity.
Malignant neoplasm of breast 1 mg orally once daily until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog concurrently or have had bilateral orchiectomy.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, thrombocytopenia
Serious myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, venous thromboembolism, hepatotoxicity including drug-induced liver injury
Postmarketing drug-induced liver injury, hypersensitivity including angioedema, erythema nodosum, rash, dermatitis
Most common (>=20%) Fatigue, nausea, vomiting, diarrhea, headache, alopecia, decreased appetite, hemoglobin decreased, neutrophils decreased, lymphocytes decreased, platelets decreased
Serious Anemia, pyrexia
Pharmacology
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes (PARP1, PARP2, PARP3) involved in DNA transcription and repair; cytotoxicity occurs through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, with enhanced activity in tumor cells harboring deficiencies in BRCA1/2, ATM, or other homologous recombination repair (HRR) genes.
Talazoparib is an inhibitor of PARP enzymes (PARP1 and PARP2) involved in DNA repair; it induces cytotoxicity in cancer cells with DNA repair gene defects through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, decreased cell proliferation, and apoptosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lynparza
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Talzenna
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Lynparza
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Talzenna
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Lynparza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Talzenna
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Lynparza Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Talzenna.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LynparzaView full Lynparza profile
TalzennaView full Talzenna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.